Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

56.17 -5.80 (-9.36%)
Streaming Delayed Price Updated: 3:51 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Prediction: 2 Stocks That Will Be Worth More Than SoundHound AI 2 Years From Now
It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies. 
Via The Motley Fool
Topics Artificial Intelligence
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. 
Via Benzinga
2 Soaring Cathie Wood Stocks to Buy and Hold
These companies' market-beating fuel hasn't run out yet. 
Via The Motley Fool
New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar.
CRISPR Therapeutics is a promising mid-cap biotech stock with an approved product in its portfolio. 
Via The Motley Fool
How Is The Market Feeling About CRISPR Therapeutics?
 
Via Benzinga
3 Monster Stocks to Hold for the Next 10 Years
Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the time. Every now and then, though, the right opportunity comes along. 
Via The Motley Fool
4 Healthcare Stocks to Buy Now
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations. 
Via The Motley Fool
Topics Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead
These biotechs could finally come into their own by the end of the decade. 
Via The Motley Fool
Topics Government World Trade
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for... 
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Growth Stocks That Could Be 10-Baggers in 10 Years
Air taxis, quantum computing, and gene editing are all promising technologies to invest in for the long haul. 
Via The Motley Fool
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
These stocks could see growth take off over the next few years. 
Via The Motley Fool
Could This Beaten-Down Stock Help You Become a Millionaire?
The company would need to maintain the strong momentum it's had this year for a long time. 
Via The Motley Fool
Topics ETFs
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
These companies are reaching key milestones. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP)
This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading the developmental race). 
Via The Motley Fool
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Peering Into CRISPR Therapeutics's Recent Short Interest
 
Via Benzinga
Cathie Wood's ARKK Is Beating Big Tech Like It's 2020 Again — But With A Twist
Cathie Wood's ARK Innovation ETF is outperforming tech market again in 2025, driven by AI breakthroughs and the return of inflows. 
Via Benzinga
Topics Artificial Intelligence ETFs
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,... 
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
This biotech's innovative approach could pay rich dividends down the road. 
Via The Motley Fool
Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade
Ark Invest has six main ETFs with several around for more than 10 years. A look at the top 10 holdings across the six funds and what it could mean. 
Via Benzinga
Topics ETFs
Cathie Wood's Ark Dumps Block Stock Worth $4.8 Million As Bitcoin-Heavy Company Preps Q2 Results
Cathie Wood-led Ark Invest executed a significant trade in Block Inc. (NYSE:XYZ) on Tuesday. 
Via Benzinga
Up 50% in 3 Months, Is This Stock Still a Buy?
This biotech's innovative ways might eventually pay off. 
Via The Motley Fool
The 3 Things That Matter for CRISPR Therapeutics Now
As time marches on, the factors that could make or break this stock are becoming crystal clear. 
Via The Motley Fool
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics
Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation. 
Via Benzinga
Cathie Wood Doesn't Need Tesla To Win—ARKK Delivers A Blowout While EV Giant Idles
During the pandemic-fueled boom of 2020, Cathie Wood's Ark Innovation ETF (NYSE:ARKK) was one of the hottest funds on Wall Street, surging nearly 400% off its March 2020 lows. But that euphoria peaked... 
Via Benzinga
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.